SRPT,CRWG,UNRH,MITK,ZIOP,UNRH,RENN,MAXD,SFIN,ZAGG -

. Currency in USD
Stock chart is not supported by your current browser
Trade prices are not sourced from all markets
Previous CloseN/A
OpenN/A
BidN/A x N/A
AskN/A x N/A
Day's RangeN/A - N/A
52 Week Rangeundefined - undefined
VolumeN/A
Avg. VolumeN/A
Market CapN/A
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Market Weekly Review: Lower Prices Create Buying Opportunities
    TipRanks16 hours ago

    Market Weekly Review: Lower Prices Create Buying Opportunities

    Despite gains for U.S. stocks on Friday, the Dow Jones Industrial Average ended lower for a fifth straight week—which is the longest streak since 2011.After a white-hot start to 2019, it’s been a wild wide for investors in the month of May. As the war of words has progressed in the trade battle between China and the U.S., price volatility has been on the increase. Use Volatility to Your AdvantageInvestors tend to shy away from volatility, which is a word that generally is only mentioned when prices are moving lower. In fact, the CBOE Volatility Index (VIX) is often referred to as the “fear gauge.”However, seasoned investors realize that volatility can be your friend. By taking a contrarian stance and buying when prices are lower, you have an opportunity to enter positions at optimal prices and boost long-term performance.“When you put it all together, this is a healthy time to come into the market for the long term,” said Thorne Perkin, president of Papamarkou Wellner Asset Management told CNBC on May 16. “We always look at these pullbacks as buying opportunities for the long term.” Short Holiday WeekThe U.S. markets will be closed next Monday for the Memorial Day holiday. In a short week, Costco (COST), Dell (DELL) and Gap (GPS) are all scheduled to report quarterly results next Thursday. On the economic front, we’ll also get a revision to the reading of first-quarter GDP growth next Thursday. The initial reading last month printed a solid 3.2%. As Memorial Day signals the unofficial start of Summer, look for trading volume to be relatively low next week. With a lot of professional investors at the beach, savvy market watchers will look to take advantage of the increased volatility that can accompany light trading volume. I know that’s the tack I will be taking with the Smart Investor portfolio next week and into the summer. Rather than shy away from any continued volatility, I’ll look to make more purchases, if the market continues to create buying opportunities.The fact remains that attractive investments are out there, if you’re willing to dig a little deeper.One such consumer name that’s worth a closer look is our Stock of the Week below… Stock of the Week: Sarepta Therapeutics (SRPT)Sarepta is a biopharmaceutical firm that’s in the business of treating rare neuromuscular diseases. The company currently has a treatment on the market for Duchenne muscular dystrophy (DMD), Exondys 51; but Sarepta is no one-trick pony. Management filed for approval of a second DMD treatment, golodirsen, in February.We recently added SRPT to our Smart Investor portfolio and are pleased to see that shares were flat compared with another down week for the broader markets. The stock has also gained 3% in the month of May, while the S&P 500 has lost nearly 4%.Looking ahead, these gains should keep on coming. Here’s why:DMD is a rare, but deadly genetic disease. The U.S. Food and Drug Administration has granted Sarepta priority review status to golodirsen and will receive an approval decision by Aug. 19, because of its potential impact. The company is not the only entrant in the DMD market, but management believes that it has at least a one-year head start on Pfizer’s (PFE) attempt to enter the arena. In total, Sarepta has a robust clinical pipeline with over 20 therapies, in various stages of research and development. Earlier this month, the company posted quarterly results that exceeded expectations. Sarepta lost $0.75 a share in the first quarter, while revenue increased 35% from the previous year, to $87 million.Yes, the company is losing money and consensus analyst estimates do not expect sustainable profitability until 2021. However, if Sarepta continues to deliver success in the clinical pipeline that day could come sooner and bring a considerably higher stock price along with it. Analysts See Higher Prices AheadIn the meantime, the analyst community is upbeat about the company’s future. 18 of 19 active analysts rate the stock a Buy (with 1 Hold) and the average price target of $202.13 suggests 67% upside potential.View SRPT Price Target & Analyst Ratings DetailAnalyst Alethia Young of Cantor Fitzgerald sums up the biopharma’s outlook here: “For Sarepta, the focus remains on continued pipeline advancement and growing gene therapy manufacturing capabilities. We continue to see many transformative updates for the company over the coming months, including a potential golodirsen approval on 8/19, potential casimersen approval in 1Q2020, and PPMO data around YE19/1Q20. Key trial initiations include commercial microdystrophin by YE19 and Charcot-Marie-Tooth in 2019.”Moreover, she adds: “We see significant revenue growth ahead with launches and also think the pipeline remains undervalued.” As a result, this top-ranked analyst reiterated her Buy rating with a bullish $231 price target on May 9. From current levels that suggests shares can surge 91%.Finally, I’m encouraged to note the stock sports a Smart Score of 10/10 on TipRanks, underlining the potential for continued price momentum. This new proprietary metric utilizes Big Data to rank stocks based on 8 key factors that have historically been a precursor of future outperformance. View SRPT Smart Score DetailIn addition to the catalysts mentioned above, Smart Score notes that Sarepta has positive sentiment from both hedge funds and investment bloggers.Looking for more top-rated stocks? Check out Analysts' Top Stocks here...

  • Thomson Reuters StreetEvents9 days ago

    Edited Transcript of ZIOP earnings conference call or presentation 8-May-19 8:30pm GMT

    Q1 2019 ZIOPHARM Oncology Inc Earnings Call

  • Thomson Reuters StreetEvents12 days ago

    Edited Transcript of SRPT earnings conference call or presentation 8-May-19 8:30pm GMT

    Q1 2019 Sarepta Therapeutics Inc Earnings Call

  • This Biotech Is More Than Its Lead Gene Therapies: Here Are 4 Drugs To Note
    Investor's Business Daily12 days ago

    This Biotech Is More Than Its Lead Gene Therapies: Here Are 4 Drugs To Note

    An analyst suggested investors look at Sarepta Therapeutics' array of gene therapies on Tuesday after rival Solid Biosciences reported its key gene therapy caused side effects in a patient.

  • Here’s What Hedge Funds Think About Mitek Systems, Inc. (MITK)
    Insider Monkey15 days ago

    Here’s What Hedge Funds Think About Mitek Systems, Inc. (MITK)

    "Market conditions are changing. The continued rise in interest rates suggests we are in the early stages of a bond bear market, which could intensify as central banks withdraw liquidity. The receding tide of liquidity will start to reveal more rocks beyond what has been exposed in emerging markets so far, and the value of […]

  • Sarepta Therapeutics (SRPT) Q1 2019 Earnings Call Transcript
    Motley Fool17 days ago

    Sarepta Therapeutics (SRPT) Q1 2019 Earnings Call Transcript

    SRPT earnings call for the period ending March 31, 2019.

  • Sarepta (SRPT) Q1 Earnings Top Estimates, Exondys 51 Sales Up
    Zacks17 days ago

    Sarepta (SRPT) Q1 Earnings Top Estimates, Exondys 51 Sales Up

    Sarepta (SRPT) beats estimates for both earnings and sales in first-quarter 2019. Exondys 51 continues to perform well on strong demand. Shares up.

  • When Can We Expect A Profit From Sarepta Therapeutics, Inc. (NASDAQ:SRPT)?
    Simply Wall St.17 days ago

    When Can We Expect A Profit From Sarepta Therapeutics, Inc. (NASDAQ:SRPT)?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...

  • Sarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates
    Zacks18 days ago

    Sarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates

    Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of 47.81% and 0.11%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press18 days ago

    Ziopharm: 1Q Earnings Snapshot

    The Boston-based company said it had a loss of 8 cents per share. The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss ...

  • Associated Press18 days ago

    Sarepta Therapeutics: 1Q Earnings Snapshot

    On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of $1.07. The results topped Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment ...

  • ZAGG (ZAGG) Q1 2019 Earnings Call Transcript
    Motley Fool18 days ago

    ZAGG (ZAGG) Q1 2019 Earnings Call Transcript

    ZAGG earnings call for the period ending March 31, 2019.

  • Zagg (ZAGG) Reports Q1 Loss, Tops Revenue Estimates
    Zacks19 days ago

    Zagg (ZAGG) Reports Q1 Loss, Tops Revenue Estimates

    Zagg (ZAGG) delivered earnings and revenue surprises of -26.47% and 1.72%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press19 days ago

    Zagg: 1Q Earnings Snapshot

    The Midvale, Utah-based company said it had a loss of 50 cents per share. Losses, adjusted for one-time gains and costs, came to 43 cents per share. The results missed Wall Street expectations. The average ...

  • Markit19 days ago

    See what the IHS Markit Score report has to say about Sarepta Therapeutics Inc.

    Sarepta Therapeutics Inc NASDAQ/NGS:SRPTView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is high * Economic output in this company's sector is expanding Bearish sentimentShort interest | NegativeShort interest is high for SRPT with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting SRPT. However, the last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment. Money flowETF/Index ownership | NeutralETF activity is neutral. The net inflows of $2.24 billion over the last one-month into ETFs that hold SRPT are not among the highest of the last year and have been slowing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Thomson Reuters StreetEvents20 days ago

    Edited Transcript of MITK earnings conference call or presentation 1-May-19 8:30pm GMT

    Q2 2019 Mitek Systems Inc Earnings Call

  • Should You Investigate ZAGG Inc (NASDAQ:ZAGG) At US$8.10?
    Simply Wall St.20 days ago

    Should You Investigate ZAGG Inc (NASDAQ:ZAGG) At US$8.10?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! ZAGG Inc (NASDAQ:ZAGG), which is in the consumer durables business, and is b...

  • Will Zagg (ZAGG) Beat Estimates Again in Its Next Earnings Report?
    Zacks20 days ago

    Will Zagg (ZAGG) Beat Estimates Again in Its Next Earnings Report?

    Zagg (ZAGG) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

  • Eaton Vance Worldwide Health Sciences Fund Buys 5 New Stocks
    GuruFocus.com24 days ago

    Eaton Vance Worldwide Health Sciences Fund Buys 5 New Stocks

    Fund releases 1st-quarter portfolio

  • Why Mitek Stock Fell Thursday
    Motley Fool24 days ago

    Why Mitek Stock Fell Thursday

    Investors can say goodbye to buyout prospects.

  • Mitek Systems (MITK) Q2 2019 Earnings Call Transcript
    Motley Fool24 days ago

    Mitek Systems (MITK) Q2 2019 Earnings Call Transcript

    MITK earnings call for the period ending March 31, 2019.

  • Thomson Reuters StreetEvents25 days ago

    Edited Transcript of MITK earnings conference call or presentation 29-Jan-19 9:30pm GMT

    Q1 2019 Mitek Systems Inc Earnings Call

  • Mitek Systems (MITK) Tops Q2 Earnings and Revenue Estimates
    Zacks25 days ago

    Mitek Systems (MITK) Tops Q2 Earnings and Revenue Estimates

    Mitek Systems (MITK) delivered earnings and revenue surprises of 40.00% and 4.02%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press25 days ago

    Mitek Systems: Fiscal 2Q Earnings Snapshot

    On a per-share basis, the San Diego-based company said it had a loss of 2 cents. Earnings, adjusted for one-time gains and costs, were 7 cents per share. The results topped Wall Street expectations. The ...

  • Benzinga25 days ago

    A Preview Of Mitek Systems Q2 Earnings

    Mitek Systems (NASDAQ: MITK ) unveils its next round of earnings this Wednesday, May 1. Here is Benzinga's everything-that-matters guide for the earnings announcement. Earnings and Revenue Wall Street ...